Calciphylaxis – Market Insights, Epidemiology and Market Forecast-2027

Albany, Feb 11, 2019 (Issuewire.com) – Calciphylaxis – Market Insights, Epidemiology and Market Forecast-2027                     

Most of the patients who have been diagnosed with calciphylaxis are female.

More on StockNewDesk:

  • According to DelveInsights estimates, total incident population (newly diagnosed) in the 7MM was approximately 2,800 in 2016 and is expected to grow at a CAGR of 0.67% for the study period [20162027].
  • Assessments by DelveInsights analysts reveal a higher incidence of Calciphylaxis is observed in the United States.
  • Among the European 5 countries, Germany had the highest incident population of calciphylaxis, followed by the United Kingdom. On the other hand, Spain had the lowest incident population in 2016. Japan has the second highest incident population of Calciphylaxis, among the 7MM countries.

(Albany, US) DelveInsight launched a new report on Calciphylaxis – Market Insights, Epidemiology and Market Forecast-2027

Request for sample pages

Key topics covered

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Calciphylaxis market.
  • Organize sales and marketing efforts by identifying the best opportunities for Calciphylaxis market.
  • To understand the future market competition in the Calciphylaxis market.

The age-specific data revealed that the highest number of people affected with Calciphylaxis were found in the age-group of 65-84 years, while people who belonged to the age group 1-17 years are the least affected

More on StockNewDesk:

The therapeutic market of Calciphylaxis in the seven major markets is expected to increase by 2027 at a Compound Annual Growth Rate (CAGR) of 4.13% for the forecast period 2016-2027. The United States had the highest market size of Calciphylaxis in 2016, which accounts for approximately 85% of the total market. On the contrary, Spain accounted for the least market share (1.20%) among the 7MM countries.

Due to the lack of approved therapeutic regimens for calciphylaxis, management involves a multidisciplinary approach consisting of primary prevention, wound care and infection prophylaxis, controlling disease progression, and treatment of the systemic disease. While a standard treatment protocol has not yet been developed for Calciphylaxis, however, according to the literature survey various therapeutic options have shown good efficacy in treating Calciphylaxis. Highlighting disease prevention i.e., by early identifying and treating renal disease with specific attention to calcium-phosphate homeostasis, is of utmost importance. 

The current therapeutic landscape of Calciphylaxis can be broadly divided into two categories: Conventional Treatment and Combination Treatment (multi-target). The mainstays of therapy include the removal of potential trigger agents, wound care, and antibiotics supplemented with intensified hemodialysis, use of chelating agents (sodium thiosulfate, and deferoxamine), and treatment of hyperparathyroidism and hyperphosphatemia with cinacalcet and non-phosphate calcium binders, respectively.

Companies covered

  • Sanifit
  • Hope Pharmaceuticals

And  many others

       Drugs covered

  • Sodium thiosulfate
  • SNF472

And many others

Table of contents

  • Key Insights
  • Calciphylaxis: Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Calciphylaxis in 2016

2.2. Total Market Share (%) Distribution of Calciphylaxis in 2027

2.3. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2016

2.4. Total Market Share (%) Distribution of Calciphylaxis by therapies in 2027

  • Calciphylaxis: Disease Background and Overview

3.1. Introduction

3.2. Clinical Manifestations

3.3. Pathophysiology of Calciphylaxis

3.3.1. Reactive Oxygen Species (ROS) in Pathogenesis of CUA/Calciphylaxis

3.4. Clinical Classification

3.5. Risk Factors of Calciphylaxis

3.5.1. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) Axis Abnormalities

3.5.2. Demographic Factors

3.5.3. Co-morbid Conditions

3.6. Diagnosis of Calciphylaxis

3.6.1. Differential Diagnosis

3.6.2. Biopsy

3.6.3. Radiological Tests and Biomarkers

3.6.4. Laboratory Evaluation

  • Epidemiology and Patient Population

4.1. Key Findings

  • Total Incident Population of Calciphylaxis in 7MM
  • Country Wise-Epidemiology of Calciphylaxis

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Incident Population of Calciphylaxis in the United States

6.1.3. Gender Specific Incident Population of Calciphylaxis in the United States

6.1.4. Age Specific Incident Population of Calciphylaxis in the United States

6.2. EU5 countries

6.2.1. Assumptions and Rationale

6.3. Germany

6.3.1. Assumptions and rationale

6.3.2. Total Incident Population of Calciphylaxis in Germany

6.3.3. Gender Specific Incident Population of Calciphylaxis in Germany

6.3.4. Age Specific Incident Population of Calciphylaxis in Germany

6.4. France

6.4.1. Assumptions and rationale

6.4.2. Total Incident Population of Calciphylaxis in France

6.4.3. Gender Specific Incident Population of Calciphylaxis in France

6.4.4. Age Specific Incident Population of Calciphylaxis in France

6.5. Italy

6.5.1. Assumptions and Rationale

6.5.2. Total Incident Population of Calciphylaxis in Italy

6.5.3. Gender Specific Incident Population of Calciphylaxis in Italy

6.5.4. Age Specific Incident Population of Calciphylaxis in Italy

6.6. Spain

6.6.1. Assumptions and Rationale

6.6.2. Total Incident Population of Calciphylaxis in Spain

6.6.3. Gender Specific Incident Population of Calciphylaxis in Spain

6.6.4. Age Specific Incident Population of Calciphylaxis in Spain

6.7. United Kingdom

6.7.1. Assumptions and Rationale

6.7.2. Total Incident Population of Calciphylaxis in the United Kingdom

6.7.3. Gender Specific Incident Population of Calciphylaxis in the United Kingdom

6.7.4. Age Specific Incident Population of Calciphylaxis in the United Kingdom

6.8. Japan

6.8.1. Assumptions and Rationale

6.8.2. Total Incident Population of Calciphylaxis in the Japan

6.8.3. Gender Specific Incident Population of Calciphylaxis in the Japan

6.8.4. Age Specific Incident Population of Calciphylaxis in Japan

  • Treatment Algorithm, Current Treatment, and Medical Practices
  • Unmet Needs
  • Emerging Therapies

9.1. Key Cross Competition

9.2. Sodium Thiosulfate: Hope Pharmaceuticals

9.2.1. Produt Description

9.2.2. Other Developmental Activities

9.2.3. Clinical Development

9.2.4. Safety and Efficacy

9.2.5. Product Profile

9.3. SNF472: Sanifit

9.3.1. Product Description

9.3.2. Other Developmental Activities

9.3.3. Clinical Development

9.3.4. Safety and Efficacy

9.3.5. Product Profile

  • Discontinued Product

10.1. Sodium thiosulfate: Luitpold Pharmaceuticals

10.1.1. Product Description

10.1.2. Clinical Development

10.1.3. Product Profile

  • Calciphylaxis: 7MM Market Analysis

11.1. Key Findings

11.2. Market Size of Calciphylaxis in 7MM countries

11.3. Market Size of Calciphylaxis by therapies in 7MM

  • United States: Market Outlook

12.1. United States Market Size

12.1.1. Total Market size of Calciphylaxis

12.1.2. Market Size of Calciphylaxis by therapies in the US

  • EU-5 countries: Market Outlook

13.1. Germany Market Size

13.1.1. Total Market size of Calciphylaxis

13.1.2. Market Size of Calciphylaxis by therapies in Germany

13.2. France Market Size

13.2.1. Total Market size of Calciphylaxis

13.2.2. Market Size of Calciphylaxis by therapies in France

13.3. Italy Market Size

13.3.1. Total Market size of Calciphylaxis

13.3.2. Market Size of Calciphylaxis by therapies in Italy

13.4. Spain Market Size

13.4.1. Total Market size of Calciphylaxis

13.4.2. Market Size of Calciphylaxis by therapies in Spain

13.5. United Kingdom Market Size

13.5.1. Total Market size of Calciphylaxis

13.5.2. Market Size of Calciphylaxis by therapies in the UK

  • Japan Market Outlook

14.1. Japan Market Size

14.1.1. Total Market size of Calciphylaxis

14.1.2. Market Size of Calciphylaxis by therapies in Japan

  • Market Drivers
  • Market Barriers
  • Appendix

17.1. Report Methodology

  • DelveInsight Capabilities
  • Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

[email protected]

+919650213330

SOURCE DelveInsight

Media Contact

Delveinsight Business Reserarch LLP

[email protected]

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com/

Source :DelveInsight

This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:

Login

Register | Lost your password?